Skip to main content

Advertisement

SpringerLink
Log in

The Individual and Combined Effects of Obesity and Type 2 Diabetes on Cancer Predisposition and Survival

  • Cancer (MF Leitzmann, Section Editor)
  • Published:
Current Nutrition Reports Aims and scope Submit manuscript

Abstract

The incidence and prevalence of obesity and type 2 diabetes mellitus continues to rise worldwide, and there is evidence which suggests that both increased body mass index (i.e., obesity) and type 2 diabetes mellitus act as independent and synergistic risk factors for the development, mortality risk, and survival of certain cancers, and thereby contribute to the increasing incidence of cancers worldwide. Numerous pathways are hypothesised to account for the independent and combined effects of obesity and diabetes on cancer predisposition and outcomes. In understanding the individual and combined effects of obesity and diabetes on cancer predisposition and survival, there are confounding factors, such as medications, biases, and weight loss, to consider.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9984):766-81.

  2. World Health Organisation. Fact sheet No. 311: obesity and overweight [Internet]. 2014 [cited 2014 Aug 28]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.

  3. International Diabetes Federation. Diabetes and Impaired Glucose Tolerance Global Burden: Prevalence and Projections, 2010 and 2030 [Internet]. [cited 2014 Aug 28]. Available from: https://www.idf.org/sites/default/files/The_Global_Burden.pdf.

  4. Lüder W. Prevention of Diabetes Mellitus. Report of a WHO Study Group. WHO Technical Report Series 844. World Health Organisation. Geneva 1994. Food Nahrung. 1995;39(3):252–3.

    Google Scholar 

  5. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.

    PubMed  Google Scholar 

  6. Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.

    CAS  PubMed  Google Scholar 

  7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D BF. No Title. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. p. Available from: http://globocan.iarc.fr.

  8. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.

    PubMed  Google Scholar 

  9. Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol. 2013;2013:583786. A recent review covering the epidemiology and pathphysiology linking diabetes and risk of cancer.

    PubMed Central  PubMed  Google Scholar 

  10. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.

    CAS  PubMed  Google Scholar 

  11. Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, et al. Diabetes and cancer–an AACE/ACE consensus statement. Endocr Pract. 2013;19(4):675–93.

    PubMed  Google Scholar 

  12. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301–16.

    CAS  PubMed  Google Scholar 

  13. Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 2003;17:73–89.

    CAS  PubMed  Google Scholar 

  14. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology. 2003;144(6):2650–8.

    CAS  PubMed  Google Scholar 

  15. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114(1):63–70.

    CAS  PubMed  Google Scholar 

  16. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620–5.

    CAS  PubMed  Google Scholar 

  17. Duggan C, Wang C-Y, Neuhouser ML, Xiao L, Smith AW, Reding KW, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer. 2013;132(5):1191–200.

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114(1):23–37.

    CAS  PubMed  Google Scholar 

  19. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the microenvironment: links to cancer. J Carcinog. 2013;12:19.

    PubMed Central  PubMed  Google Scholar 

  20. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325(5947):1555–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 1972;32(2):226–32.

    CAS  PubMed  Google Scholar 

  22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci. 2014;1311:57–76.

    CAS  PubMed  Google Scholar 

  24. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926–32.

    CAS  PubMed Central  PubMed  Google Scholar 

  25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    PubMed  Google Scholar 

  26. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    PubMed  Google Scholar 

  27. Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010;126(3):692–702.

    CAS  PubMed  Google Scholar 

  28. Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev. 2008;32(3):190–9.

    PubMed  Google Scholar 

  29. Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014. Largest population based cohort studypublished to date.

  30. Campbell PT, Cotterchio M, Dicks E, Parfrey P, Gallinger S, McLaughlin JR. Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1735–44.

    PubMed  Google Scholar 

  31. Russo A, Franceschi S, La Vecchia C, Dal Maso L, Montella M, Conti E, et al. Body size and colorectal-cancer risk. Int J Cancer. 1998;78(2):161–5.

    CAS  PubMed  Google Scholar 

  32. Rapp K, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol. 2008;19(4):641–8.

    CAS  PubMed  Google Scholar 

  33. Dobbins M, Decorby K, Choi BCK. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536. Largest meta-anlysis of obeservational studies.

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.

    CAS  PubMed  Google Scholar 

  35. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer–a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665–71.

    CAS  PubMed  Google Scholar 

  36. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65.

    PubMed Central  PubMed  Google Scholar 

  37. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.

    PubMed  Google Scholar 

  38. Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol. 2010;11(8):741–52.

    PubMed Central  PubMed  Google Scholar 

  39. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.

    PubMed Central  PubMed  Google Scholar 

  40. Henley SJ, Flanders WD, Manatunga A, Thun MJ. Leanness and lung cancer risk: fact or artifact? Epidemiology. 2002;13(3):268–76.

    PubMed  Google Scholar 

  41. Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr. 2012;32:311–42.

    CAS  PubMed  Google Scholar 

  42. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23(7):1370–8.

    PubMed  Google Scholar 

  43. Caan BJ, Kwan ML, Shu XO, Pierce JP, Patterson RE, Nechuta SJ, et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1260–71.

    PubMed Central  PubMed  Google Scholar 

  44. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486–501.

    CAS  Google Scholar 

  45. Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, et al. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer. 2013;109(11):2894–903.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Arem H, Irwin ML. Obesity and endometrial cancer survival: a systematic review. Int J Obes (Lond). 2013;37(5):634–9.

    CAS  Google Scholar 

  47. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5(7):901–10.

    Google Scholar 

  48. McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, et al. Obesity adversely affects survival in pancreatic cancer patients. Cancer. 2010;116(21):5054–62.

    PubMed Central  PubMed  Google Scholar 

  49. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–62.

    CAS  PubMed Central  PubMed  Google Scholar 

  50. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31(33):4229–34.

    PubMed Central  PubMed  Google Scholar 

  51. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.

    CAS  PubMed  Google Scholar 

  52. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011;22(8):1163–71.

    PubMed  Google Scholar 

  53. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13:310.

    PubMed Central  PubMed  Google Scholar 

  54. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer. 2013;132(9):2186–91.

    CAS  PubMed  Google Scholar 

  55. Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57(6):1576–85.

    CAS  PubMed  Google Scholar 

  56. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.

    PubMed  Google Scholar 

  57. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863–76.

    PubMed  Google Scholar 

  58. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–48.

    CAS  PubMed  Google Scholar 

  60. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.

    PubMed  Google Scholar 

  61. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331(2):81–4.

    CAS  PubMed  Google Scholar 

  62. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.

    PubMed Central  PubMed  Google Scholar 

  63. Huxley R, Ansary-Moghaddam A, de González Berrington A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056–62.

    PubMed  Google Scholar 

  65. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–8.

    CAS  PubMed  Google Scholar 

  66. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341–53.

    CAS  PubMed  Google Scholar 

  67. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161(2):147–52.

    PubMed  Google Scholar 

  68. Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.

    CAS  PubMed  Google Scholar 

  69. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53(9):1867–76.

    CAS  PubMed  Google Scholar 

  70. Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.

    CAS  PubMed  Google Scholar 

  71. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer. 2012;118(5):1353–61. Contains rare data on cancer survival in patients with and without T2DM.

    PubMed  Google Scholar 

  72. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44.

    PubMed Central  PubMed  Google Scholar 

  73. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. Epidemiology. 2014;25(3):454–61.

    PubMed Central  PubMed  Google Scholar 

  74. Hu F. Obesity epidemiology. Obesity epidemiology. New York: Oxford University Press; 2008. p. 216–33.

    Google Scholar 

  75. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2006;98(7):944–8.

    PubMed  Google Scholar 

  76. Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83(4):735–43.

    CAS  PubMed  Google Scholar 

  77. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87(4):801–9.

    CAS  PubMed  Google Scholar 

  78. Stram DO, Huberman M, Wu AH. Is residual confounding a reasonable explanation for the apparent protective effects of beta-carotene found in epidemiologic studies of lung cancer in smokers? Am J Epidemiol. 2002;155(7):622–8.

    PubMed  Google Scholar 

  79. Renehan AG, Leitzmann MF, Zwahlen M. Re: body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst. 2012;104(21):1680–1. author reply 1681.

    PubMed  Google Scholar 

  80. Maruthur NM, Bolen S, Brancati FL, Clark JM. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med. 2009;24(5):665–77.

    PubMed Central  PubMed  Google Scholar 

  81. Maruthur NM, Bolen SD, Brancati FL, Clark JM. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring). 2009;17(2):375–81.

    Google Scholar 

  82. Peacock SL, White E, Daling JR, Voigt LF, Malone KE. Relation between obesity and breast cancer in young women. Am J Epidemiol. 1999;149(4):339–46.

    CAS  PubMed  Google Scholar 

  83. Logue J, Walker JJ, Leese G, Lindsay R, McKnight J, Morris A, et al. Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care. 2013;36(4):887–93.

    PubMed Central  PubMed  Google Scholar 

  84. Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014;16(2):97-110.

  85. Van de Poll-Franse LV, Houterman S, Janssen-Heijnen MLG, Dercksen MW, Coebergh JWW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120(9):1986–92.

    PubMed  Google Scholar 

  86. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302.

    CAS  PubMed Central  PubMed  Google Scholar 

  87. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21(3):433–40.

    PubMed  Google Scholar 

  88. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100(6):1179–85.

    CAS  PubMed  Google Scholar 

  89. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2006;84(2):427–33.

    CAS  PubMed  Google Scholar 

  90. Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N, Kashkosh H, Minuchin O, et al. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J. 2005;7(3):143–7.

    PubMed  Google Scholar 

  91. Tobias DK, Pan A, Jackson CL, O’Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Martin M, Marais R. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol. 2012;30(21):2698–700.

    CAS  PubMed  Google Scholar 

  93. Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012:928127.

    PubMed Central  PubMed  Google Scholar 

  94. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 2011;1243:54–68.

    CAS  PubMed  Google Scholar 

  95. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813–22.

    CAS  PubMed Central  PubMed  Google Scholar 

  96. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7(3):e33411.

    CAS  PubMed Central  PubMed  Google Scholar 

  97. Lee JH, Il KT, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131(3):752–9.

    CAS  PubMed  Google Scholar 

  98. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35(2):299–304.

    PubMed Central  PubMed  Google Scholar 

  99. Tan B-X, Yao W-X, Ge J, Peng X-C, Du X-B, Zhang R, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 2011;117(22):5103–11.

    CAS  PubMed  Google Scholar 

  100. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care. 2008;31(7):1455–60.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184(12):E675–83.

    PubMed Central  PubMed  Google Scholar 

  102. Dormandy J, Bhattacharya M, van Troostenburg deBruyn A-R. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187–202.

    CAS  PubMed  Google Scholar 

  103. Erdmann E, Song E, Spanheimer R, van Troostenburg deBruyn A-R, Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab. 2014;16(1):63–74.

    CAS  PubMed  Google Scholar 

  104. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer. 2012;3(4):137–46.

    CAS  PubMed  Google Scholar 

  105. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668–77.

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193–201.

    CAS  PubMed  Google Scholar 

  107. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.

    CAS  PubMed  Google Scholar 

  108. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653–62.

    PubMed  Google Scholar 

  109. McCawley GM, Ferriss JS, Geffel D, Northup CJ, Modesitt SC. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg. 2009;208(6):1093–8.

    PubMed  Google Scholar 

  110. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.

    PubMed  Google Scholar 

  111. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009;17(4):796–802.

    Google Scholar 

  112. Ostlund MP, Lu Y, Lagergren J. Risk of obesity-related cancer after obesity surgery in a population-based cohort study. Ann Surg. 2010;252(6):972–6.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Ross C. McLean and Jennifer Logue declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. BHF Cardiovascular Research Centre, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK

    Ross C. McLean & Jennifer Logue

Authors
  1. Ross C. McLean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Logue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Logue.

Additional information

This article is part of the Topical Collection on Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McLean, R.C., Logue, J. The Individual and Combined Effects of Obesity and Type 2 Diabetes on Cancer Predisposition and Survival. Curr Nutr Rep 4, 22–32 (2015). https://doi.org/10.1007/s13668-014-0105-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13668-014-0105-3

Keywords

Search

Navigation